The present invention relates to use of an angiotensin II type 1 receptor (ATII) antagonist or a pharmaceutically acceptable salt thereof, particularly candesartan or candesartan cilexetil, in the manufacture of a medicament for the prevention of stroke, diabetes and/or congestive heart failure (CHF).